Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
This grant supports multidisciplinary preclinical research to understand how radionuclide radiation affects cancer and normal tissues, aiming to improve and personalize radiopharmaceutical therapies.
Funder: National Institutes of Health
Due Dates (Anticipated): October 2026 (Full application deadline, projected)
Funding Amounts: Exploratory/developmental projects: up to 2 years; research projects: 4–5 years. Typical NIH award size; total funding not specified.
Summary: Supports multidisciplinary research to advance understanding of biological effects of radionuclide-emitted radiation in preclinical cancer models, aiming to improve radiopharmaceutical therapies.
Description
This funding opportunity, led by the National Cancer Institute (NCI) at NIH, is designed to support research projects that utilize advanced cancer biology and preclinical models to investigate the biological effects of radiation emitted by radionuclides used in radiopharmaceutical therapy (RPT). The initiative, known as the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program, seeks to deepen mechanistic understanding of how different forms of radionuclide-emitted radiation impact normal tissues, tumor cells, and the tumor microenvironment. The ultimate goal is to inform the development of improved targeting strategies, treatment regimens, and innovative combination approaches for RPT, leading to more effective and precise anticancer therapies.
Projects funded under this notice are expected to integrate disciplines such as cancer biology, radiation biology, radiochemistry, imaging, dosimetry, and preclinical modeling. The program supports both exploratory/developmental projects (up to 2 years) and larger research projects (4–5 years), consolidating prior mechanisms to streamline the application process and accelerate progress in this critical area.
